oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Insights into the Roles

oral glp-1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Insights into the Roles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology - PMC

Currently, combination/multiple-drug therapy is becoming more popular than monotherapy

These statistical observations explain why companies vigorously defend against new boxes: each warning can cost millions in foregone sales and can curtail a drug’s lifecycle